In this article we will discuss Olaparib (Description-17)
Author: priyeshbanerjeept
Physiotherapist, Certified MFR therapist on a mission to provide one stop search destination for various diseases its symptoms,causes,diagnosis,treatment, physiotherapy management,rehabilitation with practical examples for aspiring physiotherapists,medical professionals and general public.
In this article we will discuss Olaparib (Description-16)
In this article, we will discuss Olaparib (Description-15). So, let’s get started. Carcinogenesis (2) In a fertility study, female rats received oral Olaparib at doses of 0.05, 0.5, and 15 mg/kg/day for at least 14 days before m*ting through the first week of pregnancy. There were no adverse effects on m*ting and fertility rates at […]
In this article we will discuss Anticancer Drugs (Description-1)
In this article we will discuss Olaparib (Description-14). So, let’s get started. Carcinogenesis Carcinogenicity studies have not been conducted with Olaparib. Olaparib was clastogenic in an in vitro chromosomal aberration assay in mammalian (CHO) cells and in an in vivo rat bone marrow micronucleus assay. This clastogenicity is consistent with genomic instability resulting from the […]